Posts by Virginia Anastassova

Start early to avoid surprises Europe’s medical device directive (MDD) is changing as a result of MDR 2017/745 published on May 5, 2017. The new regulations will come into full force in Q2 2020, after a 3 year transition period. With over 300 pages, you probably have a lot of questions about preparing for MDR […]

What is adaptive design for clinical study and why is the Medical Device community so excited about it? An adaptive design for a medical device clinical study is defined as a clinical trial design that allows for prospectively planned modifications based on accumulating study data without undermining the trial’s integrity and validity.

The Expedited Access Pathway (EAP) became effective on April 15th this year with the issue of the Food and Drug Administration (FDA or the Agency) guidance entitled  “Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions.”

The FDA is eager to show improvement of a performance self-assessment which revealed “a steady decline” of its premarket medical device approval program between 2000 and 2010. In a recent report on policies and initiatives, the FDA device arm (CDRH) claims it approves medical devices much faster than five years ago. The Agency also outlines […]

“We need a meeting with the FDA”. These words can put almost everybody in the company in panic mode. What data do we present? How long do we need to prepare the meeting package? Who will be presenting? Who will be attending the meeting? How much do we rehearse for the meeting?

Unique Device Identifiers (UDIs) have been one of the hot topics in the Medical Device world in the last few years. The FDA requirements for UDIs became a reality last year with the first compliance date of September 24th, 2014 requiring the labels and packages of class III medical devices and devices licensed under the […]